Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Meidi Xi, indicating a significant increase in stock price and trading activity [1][2] - As of November 13, Meidi Xi's stock price rose by 2.06% to 67.96 CNY per share, with a total market capitalization of 9.131 billion CNY [1] - Year-to-date, Meidi Xi's stock has increased by 125.26%, with a 2.43% rise in the last five trading days and a 10.50% increase over the past 20 days [1] Group 2 - Meidi Xi operates in the pharmaceutical and biotechnology sector, specifically in medical services and drug research outsourcing, with a revenue composition of 50.34% from preclinical research and 49.64% from drug discovery and pharmaceutical research [2] - For the period from January to September 2025, Meidi Xi reported a revenue of 843 million CNY, reflecting a year-on-year growth of 5.14%, while the net profit attributable to shareholders was -29.6849 million CNY, showing a significant increase of 76.93% [2] - The company has distributed a total of 158 million CNY in dividends since its A-share listing, with 33.9365 million CNY distributed over the past three years [3]

Group 1 - The core point of the news is that Medisi (SH 688202) announced the release of a portion of shares held by shareholder Chen Guoxing, with 4 million unrestricted circulating shares being unfrozen as of November 12, 2025 [1] - As of the announcement date, Chen Guoxing has a total of approximately 880,000 frozen shares, which accounts for 0.65% of the company's total share capital [1] - Medisi's market capitalization is currently valued at 8.9 billion yuan [3] Group 2 - For the year 2024, Medisi's revenue composition shows that the preclinical CRO business accounts for 99.96% of total revenue, while other businesses contribute only 0.04% [2]

证券代码：688202 证券简称：美迪西 公告编号：2025-068 上海美迪西生物医药股份有限公司 关于股东部分股份解除冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三、本次解除冻结的影响及风险提示 本次陈国兴先生持有的公司股份解除冻结数量为 4,000,000 股，占公司总股 本的比例为 2.98%，本次股份解除冻结后，陈国兴先生持有的公司股份尚有 875,154 股被冻结。 一、本次解除冻结的股份原冻结情况 股东陈国兴所持公司 4,875,154 股股份存在被司法冻结的情形，内容详见公 司于 2024 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）披露的《上 海美迪西生物医药股份有限公司关于股东股份被司法冻结的公告》（公告编号： 2024-052）。 二、股东持有公司股份被解除冻结的情况 公司于 2025 年 11 月 12 日收到股东陈国兴先生出具的《关于部分股份解除 冻结的告知函》，其所持公司 4,000,000 股无限售流通股已解除冻结，具体情况如 下： 1 | 股东名 ...

Core Viewpoint - The company announced that shareholder Chen Guoxing has lifted the freeze on 4 million shares, representing 2.98% of the total share capital, due to the partial lifting of a judicial freeze [1] Summary by Relevant Sections - **Shareholder Actions** - Chen Guoxing has released a total of 4 million shares from a freeze, which constitutes 2.98% of the company's total share capital [1] - There are still 875,154 shares remaining under judicial freeze [1] - **Impact on Company Control** - Chen Guoxing is not a controlling shareholder or actual controller of the company, indicating that the release of shares will not affect the company's control or daily management [1]

Core Viewpoint - MediXis has experienced a significant stock price increase of 122.90% year-to-date, with a recent slight decline of 2.03% in trading on November 12, 2023, indicating potential volatility in the stock market [1]. Group 1: Company Performance - As of November 12, 2023, MediXis's stock price is reported at 67.25 CNY per share, with a total market capitalization of 9.035 billion CNY [1]. - The company has seen a net outflow of 5.9474 million CNY in principal funds, with large orders accounting for 25.80% of total purchases and 27.83% of total sales [1]. - For the period from January to September 2025, MediXis achieved operating revenue of 843 million CNY, reflecting a year-on-year growth of 5.14%, while the net profit attributable to shareholders was -29.6849 million CNY, showing a significant year-on-year increase of 76.93% [2]. Group 2: Business Overview - MediXis, established on February 2, 2004, and listed on November 5, 2019, specializes in providing comprehensive new drug research and development services to pharmaceutical companies and other new drug research institutions [1]. - The company's revenue composition includes 50.34% from preclinical research and 49.64% from drug discovery and pharmaceutical research, with a minor contribution of 0.01% from other sources [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing, with involvement in various concept sectors such as raw materials, specialized and innovative enterprises, margin financing, artificial intelligence, and CRO concepts [2]. Group 3: Shareholder Information - As of September 30, 2023, MediXis had 16,500 shareholders, an increase of 27.83% from the previous period, with an average of 8,149 circulating shares per shareholder, which is a decrease of 21.96% [2]. - Since its A-share listing, MediXis has distributed a total of 158 million CNY in dividends, with cumulative distributions of 33.9365 million CNY over the past three years [3].

Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Shanghai Medicilon Inc, highlighting the amount of shares reduced and the shareholder's motivations for the reduction [1][2]. Shareholder Holdings - Prior to the reduction plan, shareholder Lin Changqing held 5,473,654 shares, accounting for 4.07% of the total share capital of the company. Together with his concerted actor Chen Guoxing, they held a total of 10,348,808 shares, representing 7.70% of the total share capital [1]. Reduction Plan Implementation Results - On July 19, 2025, the company disclosed a share reduction plan, where Lin Changqing intended to reduce his holdings by up to 2,000,000 shares, or 1.49% of the total share capital, due to personal funding needs. The reduction was to be executed within three months following the disclosure [2]. - As of November 10, 2025, Lin Changqing had successfully reduced his holdings by 1,542,484 shares, which is 1.15% of the total share capital, thus fulfilling the reduction plan [2][4]. - The reduction plan was completed within the specified timeframe, and the actual reduction met the planned minimum reduction quantity [3][4].

Core Viewpoint - MediX announced that shareholder Lin Changqing has completed a share reduction plan, reducing his holdings by 1,542,484 shares, which is 1.15% of the company's total share capital, as of November 10, 2025 [1] Summary by Relevant Sections - Shareholder Activity - Lin Changqing has reduced his stake in MediX through centralized bidding and block trading [1] - The reduction plan has reached its designated time frame [1]

Group 1 - The core point of the news is that Medisi has announced the completion of a share reduction plan by shareholder Lin Changqing, who has reduced his holdings by approximately 1.15% of the company's total shares, totaling around 1.54 million shares [1] - As of the latest report, Medisi's market capitalization stands at 9.2 billion yuan [3] - The company's revenue composition for the year 2024 indicates that the preclinical CRO business accounts for 99.96% of total revenue, while other businesses contribute only 0.04% [2]

证券代码：688202 证券简称：美迪西 公告编号：2025-067 股东减持计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次减持计划实施前，上海美迪西生物医药股份有限公司（以下简称"公司"） 股东林长青先生持有公司股份 5,473,654 股，占公司总股本的 4.07%，与其一致 行动人陈国兴先生合计持有公司股份 10,348,808 股股份，占公司总股本的 7.70%。 上述股份来源于公司 IPO 前取得的股份以及公司实施资本公积金转增股本， 林长青的股份已于 2022 年 11 月 7 日起解禁上市流通。 减持计划的实施结果情况 2025 年 7 月 19 日，公司于上海证券交易所网站（www.sse.com.cn）披露了 《上海美迪西生物医药股份有限公司股东减持股份计划公告》（公告编号： 2025-042），因股东自身资金需求，公司股东林长青拟通过集中竞价或大宗交易 的方式减持合计不超过所持公司股票 2,000,000 股，即不超过 ...

Company Overview - Shanghai Medicilon Inc. is located at 585 Chuan Da Road, Chuansha New Town, Pudong New District, Shanghai, and was established on February 2, 2004. The company was listed on November 5, 2019. Its main business involves providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1][2]. Financial Performance - For the period from January to September 2025, Medicilon achieved operating revenue of 843 million yuan, representing a year-on-year growth of 5.14%. The net profit attributable to the parent company was -29.68 million yuan, showing a year-on-year increase of 76.93% [2]. - Since its A-share listing, Medicilon has distributed a total of 158 million yuan in dividends, with 33.94 million yuan distributed over the past three years [3]. Stock Performance - As of November 5, Medicilon's stock price decreased by 2.01%, trading at 65.00 yuan per share, with a total market capitalization of 8.733 billion yuan. The stock has increased by 115.45% year-to-date, but has seen a decline of 7.22% over the last five trading days and 6.39% over the last 20 days [1]. - The company has appeared on the "龙虎榜" (Dragon and Tiger List) three times this year, with the most recent appearance on July 17, where it recorded a net purchase of 102 million yuan [1]. Shareholder Information - As of September 30, Medicilon had 16,500 shareholders, an increase of 27.83% from the previous period. The average number of circulating shares per person was 8,149, which decreased by 21.96% from the previous period [2]. Industry Classification - Medicilon belongs to the Shenwan industry classification of pharmaceutical biology, specifically in the medical services and medical research outsourcing sectors. It is associated with concepts such as raw materials, synthetic biology, CRO (Contract Research Organization), innovative drugs, and biopharmaceuticals [2].